John Martin, Who Built Gilead Into HIV, Hepatitis Powerhouse, Dies
01 April 2021 - 5:35AM
Dow Jones News
By Colin Kellaher
John Martin, the long-time Gilead Sciences Inc. chief who built
the biopharmaceutical company into a titan in the HIV and hepatitis
C markets, has died, Gilead said Wednesday.
Mr. Martin, who joined Gilead in 1990 as vice president of
research and development, served as chief executive from 1996 until
2016, during which he helped transform the Foster City, Calif.,
company from a money-losing biotech into a profitable
pharmaceutical company offering the blockbuster antiviral drugs
Harvoni, Sovaldi and Truvada.
In 2015, Mr. Martin's last full year as CEO, Gilead reported a
profit of $18 billion on revenue of $32.6 billion.
"John's legacy will be felt for generations to come, living on
through the scientific progress made under his leadership and the
programs he championed that expanded access to medications for
people around the world," said Daniel O'Day, Gilead's current
chairman and CEO.
Mr. Martin, who became chairman in 2008, handed the CEO reins to
John Milligan in early 2016 but remained chairman until March
2019.
Mr. Martin was also an early investor in Kronos Bio Inc. and
served on the board of the San Mateo, Calif., clinical-stage
biopharmaceutical company, which went public in October. At the
time of his death, he was also a member of the board of
genetic-medicine company Sarepta Therapeutics Inc.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 31, 2021 14:20 ET (18:20 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2024 to May 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From May 2023 to May 2024